Antisoma Venture Capital Fund

Our primary focus is on the development of novel therapeutics and platforms. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. Invest Globally: We invest in North America, Europe and Israel with approximately USD 750 million under management in committed capital. We continue our strategy of making larger focused investments and anticipate total investments up to USD 30 million per company over its life. Invest Across Healthcare Sector: We make equity investments in Biotechnology/Biopharma life sciences companies. NVF is stage agnostic and engages in seed investments as well as later-stage investments. We typically lead or co-lead an investment and play an active role on company boards.

Our portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. We take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Our global investment professionals bring deep scientific, medical and business knowledge to every investment we make. In an increasingly globalized economy, Vertex Ventures HC offers global expertise to companies around the world. With offices in Silicon Valley and Singapore, our investment team scouts and invests in promising companies in the U.S., Asia and beyond. Our team, along with our network of scientific advisors and venture partners, has deep local networks and capabilities in both emerging and established markets. Our agile structure means we can act quickly on investment opportunities.

We are Lumira Ventures. $450M+ Invested: Over more than two decades, our firm has invested over $1B via multiple investment funds. $70B+ Cumulative Revenue of Portfolio Company Products: The 40+ products brought from discovery to market by our portfolio companies have generated over $60B of cumulative revenue. 100+ Companies Funded: We leverage the lessons learned from helping create, finance and build over 100 innovative healthcare companies. 27+ Average Years Partner Experience: Our portfolio companies take advantage of one of the most experienced and stable team of venture capital partners in North America. 1B+ Patients Worldwide: The areas of medical need being tackled by our companies include diabetes, Alzheimer’s, vision loss, heart failure, asthma, infectious disease and others that impact the daily lives of over 1 billion people worldwide. Focus Geography: Canada and U.S. Stage: Mix of early, clinical and revenue stage companies that are both privately held and publically traded Sectors: Biotechnology, medical technologies, digital health and consumer healthcare solutions Strategy Lumira executes a consistent, proven investment strategy as a lead investor and active partner with our portfolio companies. We focus on companies whose products offer transformative (not incremental) improvements to patient health outcomes, and the promise of dramatic reductions in the cost of healthcare delivery. Our Canadian heritage helps us “skate to where the puck is going to be,” investing in the new science and clinical insights that we expect will be driving the next decade of patient care. Differentiation Since our inception, we’ve been a different type of venture capital investor. We often focus on backing companies in regions of North America bypassed by most other investors. We manage right-sized funds where the financial interests of our fund investors are tightly aligned with our own. And we differentiate ourselves to entrepreneurs as an investor-of-choice by helping them leverage our multi-decade team stability, global industry relationships and lessons learned from building over 100 companies over our careers.

Our expertise in biopharma and biotech investments. With decades of experience and a robust network within the biopharma and biotech industries, our team offers unparalleled insight into the scientific and financial landscapes. We are dedicated to identifying transformative therapies and supporting companies that are pioneering the future of healthcare. Empowering entrepeneurs to build leading companies Biovance Capital works closely with entrepreneurs to build leading companies with transformative treatments for patients in need. Stage: We invest in early-stage companies at seed and Series A rounds across Europe, with a focus in Southern countries. Technology: We invest in biotech companies developing therapeutics in any modality and therapeutic area. We require robust and appropriate preclinical models and patented or patentable assets before investing. Market: Large target market with a clear regulatory pathway for approval, with favorable reimbursement and pricing policies. Exit Potential: Sectors with VC/M&A or IPO activity, featuring profitable exits and multiple potential acquirers. Sustainability: During the due diligence process, sustainability risks are taken into account, and whenever identified, mitigation measures are proposed.

We support the development of novel medicines that address significant unmet medical needs. As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making. Investment strategy and approach Our investment and portfolio construction strategy builds on lessons learned and approaches perfected during the 15 years the founding team worked together. We invest in companies that are about to enter the most value-generating phase of drug development i.e. clinical stage. Our capital helps answer the question “Is there a drug that works here?” We can lead, co-lead or follow. We (almost) always take Board seats in companies we invest in and lay particular emphasis on aligning our investment objectives to fellow investors’ investment interests. We always reserve capital for future capital raises and do not do investments in which we cannot. We invest in companies where it is possible for a private investor or venture syndicate to finance the R&D program all the way to regulatory approval. Therapeutic area focus All modalities and therapeutic areas are in scope as long as the biotech company is developing a novel medicine. Out of scope are investments that are, in our judgment, incremental innovation or a pureplay regulatory or pricing story. Medical devices, digital health and diagnostics companies are out of scope. Stage of company We invest in about-to-be clinical and clinical stage companies where the investment will result in a clinical readout for the lead asset. We can invest in any private financing round irrespective of whether its termed Series A, B, C or Cross-over Platform companies are also attractive, as long as the lead asset will get to a clinical readout with the financing. Geographic footprint We invest in companies in Europe and United States. We lay particular emphasis in investing in companies with Scandinavian roots, like our Firm has, and often start and build companies in Swedish and Danish ecosystem. Diseases afflicting people does not recognize geographic boundaries, science is global, financial capital is globally distributed and human capital is globally mobile. Therefore, we believe companies need to be built with that global perspective in mind. Our Core Values DECENT We show respect at all times We act with integrity and always aim to do the right thing Being reasonable builds long-term relationships DEDICATED We work hard to deliver results for patients, our companies and our LPs We are highly professional We love what we do CONFIDENT Our combined experience is extensive – we have been there before We trust our capabilities We are supported by a strong and extensive network HUMBLE We know our limitations We know when to listen and when to ask questions We are responsible stewards of our LP’s capital

At StartUp Health, we are impact-driven entrepreneurs and investors building a global army of thousands of Health Transformers collaborating to achieve health moonshots --- from ending cancer and curing disease, like diabetes and Alzheimer’s, to delivering quality care to everyone in the world regardless of location or income. We believe that investing in and supporting a diversified global portfolio of health moonshot companies is the key to improving the health and wellbeing of humanity, while also generating healthy financial returns for investors. Since 2012, we’ve made more than 400 investments in companies across 27 countries, and currently have a portfolio of 260+ active companies. We have a flexible, work-from-anywhere policy as our team is fully remote, with team members in NYC, San Francisco, Los Angeles, Baltimore, and Philadelphia. We are open to candidates across the U.S. Benefits include health insurance and long-term disability coverage, 401k with employer matching, employee stock options, and generous time off policy including paid holidays.